ALLO News and Press, Allogene Therapeutics Inc. From 10/26/23

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2023 financia...

2023-10-16 09:01:57 ET More on Allogene Therapeutics Allogene Therapeutics, Inc. (ALLO) Q2 2023 Earnings Call Transcript Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before For further details see: Allogene Therapeutics appoints Geoffrey P...

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™ ) products for cancer, has appointed Geoffrey Parker as Executive Vice President...

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune Cells Evaluation of Cloak™ Tec...

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming invest...

2023-09-01 20:00:14 ET Summary CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf cell therapies. B...

2023-08-02 19:39:02 ET Allogene Therapeutics, Inc. (ALLO) Q2 2023 Earnings Conference Call August 02, 2023 05:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President & Chief Executive Officer Zachary Roberts - E...

2023-08-02 16:09:04 ET Allogene Therapeutics press release ( NASDAQ: ALLO ): Q2 GAAP EPS of -$0.53 beats by $0.06 . Revenue of $0.04M (-55.6% Y/Y) beats by $0.02M . The Company had $544.5 million in cash, cash equivalents, and investments as of June 30, 2023, w...

Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and International Conference on Malignant Lymphoma (ICML) Lugano ALLO-501/501A Demonstrated Rates of D...

2023-07-26 19:30:39 ET Summary Allogene Therapeutics, Inc. is the leading developer of allogeneic CAR-T. There was a time when its logic appealed to me. Lately, however, I have increasingly become disillusioned about its prospects. Lest we forget with all the C-suite...